Literature DB >> 18059483

Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.

E Atallah, R Nussenzveig, C C Yin, C Bueso-Ramos, C Tam, T Manshouri, S Pierce, H Kantarjian, S Verstovsek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18059483     DOI： 10.1038/sj.leu.2405054

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Authors:  Julien Broseus; Lourdes Florensa; Esther Zipperer; Susanne Schnittger; Luca Malcovati; Steven Richebourg; Eric Lippert; Jaroslav Cermak; Jyoti Evans; Morgane Mounier; José Maria Raya; François Bailly; Norbert Gattermann; Torsten Haferlach; Richard Garand; Kaoutar Allou; Carlos Besses; Ulrich Germing; Claudia Haferlach; Erica Travaglino; Elisa Luno; Maria Angeles Pinan; Leonor Arenillas; Maria Rozman; Maria Luz Perez Sirvent; Bernardine Favre; Julien Guy; Esther Alonso; Nuhri Ahwij; Andrés Jerez; Sylvie Hermouet; Marc Maynadié; Mario Cazzola; François Girodon
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

Review 2.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 3.  Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors:  C C Yin; L J Medeiros; C E Bueso-Ramos
Journal:  Int J Lab Hematol       Date:  2010-07-07       Impact factor: 2.877

Review 4.  Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Authors:  Zhuang Zuo; Shaoying Li; Jie Xu; M James You; Joseph D Khoury; C Cameron Yin
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 5.  Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.

Authors:  Martha Wadleigh; Ayalew Tefferi
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

Review 6.  Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Authors:  Ayalew Tefferi; Radek Skoda; James W Vardiman
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

Review 7.  Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.

Authors:  Laura Palomo; Pamela Acha; Francesc Solé
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 8.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

9.  Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms.

Authors:  Huanling Wu; Shuquan Bian; Jingxue Chu; Xiaoyan Zhong; Hui Sun; Bingchang Zhang; Zhiming Lu
Journal:  Exp Ther Med       Date:  2013-02-26       Impact factor: 2.447

10.  Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.

Authors:  C D DiNardo; N Daver; N Jain; N Pemmaraju; C Bueso-Ramos; C C Yin; S Pierce; E Jabbour; J E Cortes; H M Kantarjian; G Garcia-Manero; S Verstovsek
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.